BR112021017661A2 - Uso de compostos 8,9-di-hidrocanabidiol - Google Patents
Uso de compostos 8,9-di-hidrocanabidiolInfo
- Publication number
- BR112021017661A2 BR112021017661A2 BR112021017661A BR112021017661A BR112021017661A2 BR 112021017661 A2 BR112021017661 A2 BR 112021017661A2 BR 112021017661 A BR112021017661 A BR 112021017661A BR 112021017661 A BR112021017661 A BR 112021017661A BR 112021017661 A2 BR112021017661 A2 BR 112021017661A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- dihydrocannabidiol
- seizures
- mitigating
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
- C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/26—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815735P | 2019-03-08 | 2019-03-08 | |
| PCT/US2020/021670 WO2020185661A1 (en) | 2019-03-08 | 2020-03-09 | Use of 8,9-dihydrocannabidiol compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021017661A2 true BR112021017661A2 (pt) | 2021-11-16 |
Family
ID=72426794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021017661A BR112021017661A2 (pt) | 2019-03-08 | 2020-03-09 | Uso de compostos 8,9-di-hidrocanabidiol |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250152520A2 (https=) |
| EP (1) | EP3935037A4 (https=) |
| JP (1) | JP7620984B2 (https=) |
| CN (1) | CN113874344B (https=) |
| AU (1) | AU2020236953A1 (https=) |
| BR (1) | BR112021017661A2 (https=) |
| CA (1) | CA3132841A1 (https=) |
| WO (1) | WO2020185661A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021150885A1 (en) * | 2020-01-24 | 2021-07-29 | Perkinelmer Health Sciences, Inc. | Cannabinoid derivatives |
| CN114507153B (zh) * | 2020-11-17 | 2025-06-24 | 中国科学院上海药物研究所 | 一类间苯二酚化合物及其制备方法以及在神经系统疾病中的应用 |
| CN113372196B (zh) * | 2021-07-02 | 2022-09-30 | 江南大学 | 8,9-二氢大麻二酚及其合成方法与应用 |
| WO2024006896A1 (en) * | 2022-06-29 | 2024-01-04 | The Regents Of The University Of California | Uses of hydrogenated cannabidiol (h4cbd) and advanced metabolic syndrome |
| AU2024359022A1 (en) * | 2023-10-10 | 2026-04-09 | Jazz Pharmaceuticals Research Uk Limited | Cannabinoid compounds and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018777A (en) * | 1975-11-14 | 1977-04-19 | Abbott Laboratories | 2-Substituted-5-alkyl resorcinols |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2530001B (en) * | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| CN108024973A (zh) * | 2015-07-16 | 2018-05-11 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 氟化的cbd化合物、其组合物以及用途 |
| CN108785298A (zh) * | 2017-04-27 | 2018-11-13 | 汉义生物科技（北京）有限公司 | 一种用于治疗癫痫的药物组合物、其制备方法及用途 |
| CN109106699A (zh) * | 2017-06-23 | 2019-01-01 | 汉义生物科技（北京）有限公司 | 一种用于治疗癫痫的药物组合物、其制备方法及用途 |
-
2020
- 2020-03-09 CA CA3132841A patent/CA3132841A1/en active Pending
- 2020-03-09 BR BR112021017661A patent/BR112021017661A2/pt unknown
- 2020-03-09 WO PCT/US2020/021670 patent/WO2020185661A1/en not_active Ceased
- 2020-03-09 AU AU2020236953A patent/AU2020236953A1/en not_active Abandoned
- 2020-03-09 CN CN202080030186.9A patent/CN113874344B/zh active Active
- 2020-03-09 EP EP20769683.2A patent/EP3935037A4/en active Pending
- 2020-03-09 US US17/436,015 patent/US20250152520A2/en active Pending
- 2020-03-09 JP JP2021553059A patent/JP7620984B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20250152520A2 (en) | 2025-05-15 |
| JP7620984B2 (ja) | 2025-01-24 |
| EP3935037A4 (en) | 2023-03-22 |
| CN113874344B (zh) | 2025-05-27 |
| JP2022525038A (ja) | 2022-05-11 |
| US20220183998A1 (en) | 2022-06-16 |
| AU2020236953A1 (en) | 2021-09-30 |
| WO2020185661A1 (en) | 2020-09-17 |
| EP3935037A1 (en) | 2022-01-12 |
| CA3132841A1 (en) | 2020-09-17 |
| CN113874344A (zh) | 2021-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021017661A2 (pt) | Uso de compostos 8,9-di-hidrocanabidiol | |
| SA520411125B1 (ar) | Nlrp مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط | |
| CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
| MX2023000081A (es) | Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor. | |
| BR112022004451A2 (pt) | Antagonistas de hpk1 e usos dos mesmos | |
| MY206796A (en) | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma | |
| MY209340A (en) | Egfr inhibitor for the treatment of cancer | |
| EA201800444A1 (ru) | Производные майтанзиноида, их конъюгаты и способы использования | |
| MY208545A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| PH12019502286A1 (en) | Process for preparing an optically active pyrimidinium compounds | |
| MY200590A (en) | Compounds useful as kinase inhibitors | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| CL2019001381A1 (es) | Método para el tratamiento de glomeruloesclerosis segmentaria focal. | |
| EA201892147A1 (ru) | Бициклические соединения | |
| CL2021003513A1 (es) | Compuestos heterocíclicos, como inhibidores de bet; composición, útil para tratar cáncer. | |
| EA201890256A1 (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
| ZA202309446B (en) | Rapamycin analogs and uses thereof | |
| EA202091906A1 (ru) | Предотвращение или уменьшение роста растений путем биоцементации | |
| JOP20210050B1 (ar) | معدلات تعبير pnpla3 | |
| MA50398A (fr) | Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma | |
| TN2017000196A1 (en) | 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139 | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| MX2021010152A (es) | Moduladores de la expresion de malat1. | |
| MX2025010903A (es) | Compuestos polimorficos y usos de los mismos | |
| PE20210109A1 (es) | Moduladores de la expresion de irf4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |